Dermorphin
Dermorph
Dermorphin is a naturally occurring seven-amino acid opioid peptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) first isolated from the skin secretions of South American tree frogs of the genus Phyllomedusa. It is approximately 30-40 times more potent than morphine as a mu-opioid receptor agonist and contains the unusual D-alanine residue at position 2, making it one of the first discovered naturally occurring D-amino acid-containing peptides. It has gained notoriety for its illegal use in horse racing as a performance enhancer and pain masking agent.
Wirkmechanismus
Naturally occurring heptapeptide isolated from the skin of South American tree frogs (Phyllomedusa). Potent and selective mu-opioid receptor agonist — approximately 30-40 times more potent than morphine. Contains D-alanine, which is rare in natural peptides.
Forschungsprotokolle
Nur für Forschungszwecke. Keine medizinische Beratung.
Not recommended for human research due to extreme potency and opioid receptor agonism. Primarily of academic interest. Studied in pharmacological research for understanding mu-opioid receptor selectivity.
Forschungsnotizen
Clinical Research Status
Dermorphin has not been developed for human clinical use and has no active clinical trials or regulatory filings for any therapeutic indication. Research has been confined to pharmacological characterization, opioid receptor binding studies, and development of detection methods for equine anti-doping enforcement. It serves primarily as a research tool for understanding mu-opioid receptor pharmacology and the evolution of bioactive peptides in amphibian defense secretions.
Key Published Findings
Binding studies demonstrate that dermorphin has exceptionally high selectivity and affinity for mu-opioid receptors (Ki approximately 0.2-1.6 nM), significantly exceeding morphine in both potency and selectivity. The D-alanine residue at position 2 confers resistance to aminopeptidase degradation, extending its biological half-life compared to L-amino acid-containing endogenous opioid peptides. Research on dermorphin and its analogs has contributed significantly to understanding structure-activity relationships at the mu-opioid receptor and has led to development of several research tools for opioid pharmacology.
Safety Profile
As an extremely potent mu-opioid agonist, dermorphin carries all the risks associated with opioid intoxication including respiratory depression, profound sedation, physical dependence, and potentially fatal overdose. No therapeutic index has been established for humans, and the steep dose-response curve of highly potent opioids makes accidental overdose a significant risk. The absence of human pharmacokinetic data means that dosing, onset, duration, and drug interactions are completely unknown in clinical contexts.
Comparison to Related Compounds
Dermorphin is significantly more potent than morphine (30-40x) and fentanyl-like in its receptor binding affinity, though it maintains high mu-selectivity unlike some synthetic opioids that have broader receptor profiles. Its natural analog deltorphin (from the same frog species) is similarly potent but selective for delta-opioid receptors rather than mu-receptors. Compared to endogenous opioid peptides (endorphins, enkephalins), dermorphin's D-amino acid content provides superior metabolic stability and greater pharmacological potency.
Community Observations
Dermorphin is primarily known in the public sphere through horse racing scandals, where it has been detected in post-race urine samples from winning horses in multiple US states including Louisiana, Oklahoma, and New Jersey. Its use in horse racing is considered animal abuse by regulatory bodies, as it masks pain and allows injured horses to race at risk of catastrophic breakdown. Human recreational use is extremely rare due to limited availability and the extreme danger posed by its potency, with the research community treating it primarily as a pharmacological tool rather than a potential therapeutic.
Halbwertszeit
~2-3 hours
Rekonstitution
Sterile saline
Lagerung
Lyophilisiert
Store at -20C.
Rekonstituierter
Refrigerate 2-8C. Use within 7 days.
Rechtsstatus USA
Auch bekannt als
Häufig gestellte Fragen
Was ist Dermorphin?
Dermorphin is a naturally occurring seven-amino acid opioid peptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) first isolated from the skin secretions of South American tree frogs of the genus Phyllomedusa. It is approximately 30-40 times more potent than morphine as a mu-opioid receptor agonist and contains the unusual D-alanine residue at position 2, making it one of the first discovered naturally occurring D-amino acid-containing peptides. It has gained notoriety for its illegal use in horse racing as a performance enhancer and pain masking agent.
Wie wirkt Dermorphin?
Naturally occurring heptapeptide isolated from the skin of South American tree frogs (Phyllomedusa). Potent and selective mu-opioid receptor agonist — approximately 30-40 times more potent than morphine. Contains D-alanine, which is rare in natural peptides.
Wie ist der regulatorische Status von Dermorphin in den USA?
Not scheduled but DEA analog act may apply
Wie lang ist die Halbwertszeit von Dermorphin?
~2-3 hours
Wie wird Dermorphin noch genannt?
Dermorph
Peptide Contacts bietet wissenschaftliche Zusammenfassungen für informationstechnische Zwecke an. Wir stellen keine Dokumentationen von Anbietern, keine Host- und keine Vertriebsdienstleistungen zur Verfügung und unterstützen keine Anbieter in irgendeiner Weise. Alle Zertifikate der Analyse, GMP-Zertifikate und Kommunikationen mit Anbietern müssen direkt vom Käufer angefordert und überprüft werden. Alles auf dieser Plattform stellt weder rechtliche, medizinische noch berufsmäßige Beratung dar. Nutzer sind allein verantwortlich für die Überprüfung der Anbieterzertifikate und das Gewährleisten des Einhaltens aller anwendbaren lokalen, zuständigen und federalen Gesetze beim Kauf von Forschungschemikalien. Die Nutzung dieser Plattform bedeutet die Annahme volles persönlichen Verantwortlichkeitsbewusstseins.
Ganze Erklärung lesen